What the “Wolverine protocol” actually is
The “Wolverine protocol” is community shorthand — a nod to the comic-book character’s rapid healing — for combining two of the most-studied regeneration peptides: BPC-157 and TB-500. There is no official protocol, no clinical definition and no human trial of the pair. What there is is a clear mechanistic rationale for why researchers study them together, drawn from separate preclinical work on each compound.
Why combine them: complementary mechanisms
The case for the stack is that the two peptides operate on different parts of the same repair problem. One works mostly locally; the other works systemically.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Pentadecapeptide derived from a gastric protein | Synthetic fragment of Thymosin Beta-4 |
| Primary action | Local cytoprotection + angiogenesis (VEGF pathway) | Systemic actin regulation + cell migration |
| Reach | Acts strongly at the site, well-studied in tendon/gut | Distributes broadly, supports migration to the injury |
| Role in the stack | Builds the local blood supply for repair | Brings cells to the repair zone |
Put simply: TB-500 is studied for getting repair cells to the site, while BPC-157 is studied for building the local vascular bed that supports them. Because those roles are complementary rather than duplicative, the combination is one of the most documented pairings in regeneration research — even though, to be clear, that documentation is preclinical and the two are sold only as research reagents.
Reconstituting the stack
Both peptides ship as lyophilized powder and are reconstituted with bacteriostatic water — separately, each in its own vial. Concentration is simply mass divided by volume.
- Bring both vials and the bacteriostatic water to room temperature (about 15 minutes).
- Swab the rubber stopper of every vial — both peptides and the water — with alcohol.
- Reconstitute each peptide separately. For a 10 mg BPC-157 vial, 2 mL of bacteriostatic water gives 5 mg/mL; for a 10 mg TB-500 vial, 2 mL gives 5 mg/mL as well.
- Angle the needle against the inner glass wall and let the water trickle down — never spray it onto the lyophilized cake.
- Roll each vial gently between your palms until clear. Never shake either peptide.
- Keep the two peptides in their own vials; reconstituting them together is unnecessary and complicates concentration tracking.
- Store both reconstituted solutions at 2–8 °C, protected from light, and use within 3 weeks.
For the full concentration-math walkthrough — how to convert a µg target into a number of units to draw on an insulin syringe — see the BPC-157 dosage guide, which uses the same method for both peptides, and the reconstitution guide for the worked volume tables.
Dosage ranges reported in research
These figures come from animal models and are reference points for laboratory work, not human guidance:
- BPC-157 — roughly 1–10 µg per kg of bodyweight per day in preclinical protocols.
- TB-500 — roughly 2–10 µg per kg per dose, applied a few times per week.
If you only want to understand how the two differ rather than how they combine, the TB-500 vs BPC-157 comparison breaks down the distinctions side by side.
Sourcing both peptides
A stack is only as good as its weakest vial, so the verification standard applies to each compound independently: ≥99% HPLC purity on a recent batch COA from a named laboratory such as Janoshik, identity confirmed by mass spectrometry, a clean white lyophilizate, and a vial sealed under vacuum or inert gas. The cross-compound view of purity and storage lives in the complete research peptides guide.